Intravenous Infusions Plc (GHSE:IIL)

Intravenous Infusions Income Statement

Financials in millions GHS. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	24.94	31.42	20.36	22.67	20.67
Revenue Growth (YoY)	-20.61%	54.34%	-10.21%	9.69%	-10.47%
Cost of Revenue	13.39	14.14	11.6	12.04	10.49
Gross Profit	11.55	17.28	8.76	10.63	10.18
Selling, General & Admin	10.07	9.96	11.39	8.86	7.81
Operating Expenses	10.73	10.76	11.96	9.41	8.52
Operating Income	0.82	6.52	-3.21	1.23	1.66
Interest Expense	-0.14	-0.72	-0.39	-0.15	-0.33
Other Non Operating Income (Expenses)	-1.17	-2.35	0.06	0.36	0.03
EBT Excluding Unusual Items	-0.49	3.44	-3.54	1.43	1.36
Gain (Loss) on Sale of Assets	0.01	0.05	0	-	-
Pretax Income	-0.49	3.49	-3.53	1.43	1.36
Income Tax Expense	0.16	0.95	-0.02	0.29	-0.09
Net Income	-0.64	2.54	-3.51	1.15	1.45
Net Income to Common	-0.64	2.54	-3.51	1.15	1.45
Net Income Growth	-	-	-	-20.99%	-22.44%
Shares Outstanding (Basic)	274	274	274	274	274
Shares Outstanding (Diluted)	274	274	274	274	274
Shares Change (YoY)	-	-	-	-	7.09%
EPS (Basic)	-0.00	0.01	-0.01	0.00	0.01
EPS (Diluted)	-0.00	0.01	-0.01	0.00	0.01
EPS Growth	-	-	-	-21.00%	-27.57%
Free Cash Flow	6.26	2.39	0.45	-3.86	-4.46
Free Cash Flow Per Share	0.02	0.01	0.00	-0.01	-0.02
Dividend Per Share	-	0.004	-	-	0.003
Dividend Growth	-	-	-	-	-33.86%
Gross Margin	46.31%	55.01%	43.02%	46.91%	49.27%
Operating Margin	3.28%	20.74%	-15.76%	5.42%	8.03%
Profit Margin	-2.58%	8.10%	-17.24%	5.06%	7.02%
Free Cash Flow Margin	25.09%	7.59%	2.22%	-17.03%	-21.58%
EBITDA	1.47	7.31	-2.64	1.76	2.36
EBITDA Margin	5.89%	23.27%	-12.98%	7.79%	11.41%
D&A For EBITDA	0.65	0.79	0.56	0.54	0.7
EBIT	0.82	6.52	-3.21	1.23	1.66
EBIT Margin	3.28%	20.74%	-15.76%	5.42%	8.03%
Effective Tax Rate	-	27.17%	-	19.97%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.